Home › Compare › BRPHF vs ABBV
BRPHF yields 9.20% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 2
Combined, BRPHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BRPHF + ABBV for your $10,000?
Galaxy Digital Holdings Ltd., an asset management firm, operates in the digital asset, cryptocurrency, and blockchain technology industry. It operates through five segments: Trading, Principal Investments, Asset Management, Investment Banking, and Mining. The company provides spot, derivate, and financing liquidity to institutional clients, counterparties, and venues that transact in cryptocurrencies and other digital assets; and offers access to traded cryptocurrencies to clients and counterparties across a suite of service offerings, including over-the-counter (OTC) spot liquidity provision, on- exchange liquidity provision, OTC options and trading, and bespoke lending and structured products, as well as engages in the proprietary quantitative, arbitrage, and macro trading strategies. It also manages third party capital across traditional and alternative asset classes. In addition, the company offers financial advisory services, such as general corporate, strategic, mergers and acquisitions, divestitures, and restructuring advisory services, as well as equity, debt, and project finance capital markets services to public and private clients. Further, it has a strategic focus to provide financial tools to North American miners, as well as has partnership with third-party data center providers and hosts its proprietary bitcoin mining equipment for helping to secure the Bitcoin network. Additionally, the company manages various portfolio of private investments across the digital assets industry, such as traditionally structured companies, as well as in those building digital asset networks powered and capitalized by tokens. Galaxy Digital Holdings Ltd. is headquartered in New York, New York.
Full BRPHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.